New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
06:06 EDTGLMDGalmed Pharmaceuticals 2.83M share IPO priced at $13.50
The deal size was increased to 2.83M shares from 2.35M shares and priced between the $12.00-$14.00 range. Maxim acted as lead book running manager for the offering.
News For GLMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
09:16 EDTGLMDGalmed and Itamar Medical announce collaboration
Galmed announced that it purchased 60 EndoPAT devices and accessories from Itamar Medical whose technology has been cleared by the FDA for endothelial, or arterial, function assessment, which is a novel risk marker for cardiovascular disease. Galmed intends to use Itamar Medical's EndoPAT technology to include an assessment of endothelial function in its planned Phase IIb clinical trial of its drug candidate, aramchol, involving 240 Non-Alcoholic Steato-Hepatitis, or NASH, patients suffering from obesity and insulin resistance. As Galmed previously disclosed, this Phase IIb clinical trial is expected to begin later this year and involve medical centers within the European Union, Israel and Latin America.
September 23, 2014
10:49 EDTGLMDGalmed receives FDA approval of fast track designation for Aramchol
Galmed announced that the FDA approved its request for Fast Track Designation of its product candidate, aramchol, for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. NASH is a chronic disease that affects approximately 12% of the population in United States and in certain European Union nations and its prevalence is expected to increase in parallel with increased rates of obesity and diabetes. There are currently no approved drugs for the treatment of NASH.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use